Serotonin receptor physiology: Relation to emesis

Digestive Diseases and Sciences

Volumn 44, Issue 8 SUPPL., 1999, Pages

  Hasler, William L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Nausea; Serotonin receptors; Signal transduction; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; RECEPTOR SUBTYPE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN;

ANTIEMETIC ACTIVITY; CONFERENCE PAPER; DYSPEPSIA; HEADACHE; HUMAN; HYPEREMESIS GRAVIDARUM; MIGRAINE; NAUSEA; PRIORITY JOURNAL; STOMACH PARESIS; VOMITING;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; ENTERIC NERVOUS SYSTEM; FEMALE; HUMANS; INFANT; MALE; PERIODICITY; RECEPTORS, SEROTONIN; SEROTONIN AGENTS; SYNDROME; VOMITING;

EID: 0032872312     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-204, 1994
2. Hoyer D, Martin G: 5-HT receptor classification and nomenclature: Towards a harmonization with the human genome. Neuropharmacology 36:419-428, 1997
3. Uphouse I.: Multiple serotonin receptors: too many, not enough, or just the right number? Neurosci Biobehav Rev 21:679-698, 1997
4. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399-412, 1991
5. 1-like receptor mediates a pertussis toxin-sensitive inhibition of rat ventromedial hypothalamic neurons in vitro. Br J Pharmacol 95:6-8, 1988
6. 2 receptors to decrease potassium conductance in rat nucleus accumbens neurons. J Physiol 417:1-12, 1989
7. 4 receptor. Naunyn-Schmiedeberg's Arch Pharmacol 346:496-503, 1986
8. 2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Mol Pharmacol 45:1120-1128, 1994
9. Saxena PR: Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 66:339-368, 1995
10. Gershon MD: Serotonin: Its role and receptors in enteric neurotransmission. Adv Exp Med Biol 294:221-230, 1991
11. Galligan JJ: Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Behav Brain Res 73:199-201, 1996
12. 3 receptors. Trends Neurosci 9:424-429, 1986
13. 1P receptors on sensory CGRP neurons. Am J Physiol 270:G778-G782, 1996
14. Foxx-Orenstein AE, Kuemmerle JF, Grider JR: Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 111:1281-1290, 1996
15. 4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol 271:G849-G857, 1996
16. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaiser I.: Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116-123, 1997
17. Cubeddu LX: Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53(suppl 1):18-25, 1996
18. Fukui H, Yamamoto M, Ando T, Sasaki S, Sato S: Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis. Neuropharmacology 32:959-968, 1993
19. 3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 59:221-226, 1992
20. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:846-848, 1990
21. Jantunen IT, Kataja VV, Muhonen TT: An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66-74, 1997
22. Minami M, Endo T, Hirafuji M: Role of serotonin in emesis. Nippon Yakurigaka Zasshi Fol Pharmacol Jpn 108:233-242, 1996
23. Hawthorn J, Ostler KJ, Andrews PLR: The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret. J Exp Physiol 73:7-21, 1988
24. 3 receptors and vagal afferents in copper sulfate-and cisplatin-induced emesis in monkeys. Eur J Pharmacol 249:13-18, 1993
25. Miller AD, Nonaka S: Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: Effect of vagotomy, splanchnicectomy or area postrema lesion. J Pharmacol Exp Ther 260:509-517, 1992
26. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247-255, 1989
27. 3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs. J Pharmacol Exp Ther 273:695-701, 1995
28. Fredrikson M, Hursti TJ, Steineck G, Furst CJ, Borjesson S, Peterson C: Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 70:642-645, 1994
29. Morrow GR, Rosenthal SN: Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53(suppl 1):4-7, 1996
30. Roberts JT, Priestman TJ: A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 50:173-179, 1993
31. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ: Efficacy, dose-response, and safely of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 87:1271-1273, 1997
32. Currow DC, Coughlan M, Fardell B, Cooney NJ: Use of ondansetron in palliative medicine. J Pain Symptom Manage 13:302-307, 1997
33. 3 antagonist ondansetron (Zofran). Postgrad Med J 72:688-689, 1996
34. Abell TL, Werkman R, Voeller G, Rashed H, Kumar A, Kuns J, Taylor J: Long-term therapy with ondansetron is effective in patients with refractory nausea and vomiting. Gastroenterology 108:A1, 1995 (abstract)
35. 4 receptors? Eur J Pharmacol 212:51-59, 1992
36. 4) receptor agonists on the guinea-pig colon ascendens. Naunyn-Schmiedeberg's Arch Pharmacol 347:464-470, 1993
37. Monkovic I, Willner D, Adam MA, Brown M, Crenshaw RR, Fuller CE, Juby PF, Luke GM, Matiskella JA, Montzka TA: Substituted benzamides I. Potential non-dopaminergic antagonists of chemotherapy-induced nausea and emesis. J Med Chem 31:1548-1558, 1988
38. Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ: Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 93:311-315, 1987
39. Havelund T, Oster-Jorgensen F, Eshoj O, Larsen ML, Lauritsen K: Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus. A double-blind controlled trial. Acta Med Scand 222:339-343, 1987
40. Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L: Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 28:300-305, 1987
41. de Caestecker JS, Ewing DJ, Tothill P, Clarke BF, Heading RC: Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: An eight-week double-blind crossover study. Aliment Pharmacol Ther 3:69-81, 1989
42. Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR: Effect of six weeks treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 96:704-712, 1989
43. Rosch W: Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 22:161-164, 1987
44. Wood SF, Penney SC, Cochran KM: Cisapride in functional dyspepsia: A double-blind, placebo-controlled randomized trial in general practice patients. Scand J Gastroenterol Suppl 195:5-10, 1993
45. Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A: Metoclopramide to treat gastroparesis due to diabetes mellitus. A double-blind, controlled trial. Ann Intern Med 96:444-446, 1982
46. Johnson AG: Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. Br Med J 2:25-26, 1971
47. 4 receptor mechanism. J Pharmacol Exp Ther 264:240-248, 1993
48. Briejer MR, Van Daele P, Bosmans JP, Ghoos E, Eelen J, Schuurkes JA: Dose-dependent effects after oral and intravenous administration of RO-93877 on colonie motility in conscious dogs. Gastroenterology 112: A704, 1997 (abstract)
49. 3 antagonist action in the control of emesis. Pharmacol Res 31:257-260, 1995
50. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B: Oral sumatriptan for the long-term treatment of migraine: Clinical findings. Neurology 45(8 suppl 7):S15-S20, 1995
51. Benson JM, Zorn SL, Book LS: Sumatriptan in the treatment of cyclic vomiting. Ann Pharmacother 29:997-999, 1995
52. Huang S, Lavine JH: Efficacy of sumatriptan in aborting attacks of cyclic vomiting. Gastroenterology 112:A751, 1997 (abstract)
53. 4 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol 272:G902-G908, 1997
54. 1 receptor activation has a major impact on gastrointestinal functions in man. Gastroenterology 110:A1123, 1996 (abstract)
55. 3H]sumatriptan-binding sites in post-mortem human brain. Cephalalgia 16:287-288, 1996
56. 4 receptors in copper sulfate-induced vomiting in dogs. Eur J Pharmacol 257:47-52, 1994
57. 4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol 204:273-280, 1991
58. 1A receptor agonists in Suncus murinus. Jpn J Pharmacol 64:109-114, 1994
59. 2 receptor agonist in Suncus murinus. Br J Pharmacol 114:931-934, 1995.